Medicago in funding talks for U.S. vaccine plant

Medicago (TSX:MDG) has begun negotiating final terms and conditions with the U.S. Defense Advanced Research Projects Agency (DARPA) for a financing package to build a scalable plant to make plant-expressed, virus-like particles (VLP) vaccines. Medicago submitted its proposal for the plant in March, 2010.  ”Our proposal being selected by DARPA for potential funding demonstrates our [...]

Medicago to present at WHO meeting

Medicago (TSX:MDG) will present its Phase 1 clinical findings of the first plant-made influenza vaccine to be tested in humans at a meeting this week of the World Health Organization, evaluating pandemic influenza prototype vaccines in clinical trials. “It is a privilege to be among a select group of leading vaccine companies invited to present [...]